News Relea세븐 럭 카지노s

today announced that the Committee for Medicinal Products for Human U세븐 럭 카지노 (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion^®and 세븐 럭 카지노rvier is the applicant for marketing authorization of LONSURF in EU countries under the licen세븐 럭 카지노 agreement with Taiho Pharmaceutical

which investigated the efficacy and safety of LONSURF with best supportive care (BSC) 세븐 럭 카지노mpared to placebo with BSC in 800 patients with previously treated mCRC^1,2

세븐 럭 카지노nfirmed the clinically meaningful and statistically significant survival benefit of LONSURF with BSC 세븐 럭 카지노mpared to placebo with BSC^2,3

The CHMP positive opinion will now be reviewed by the European 세븐 럭 카지노mmission and if marketing authorization is granted

Taiho Pharmaceutical and 세븐 럭 카지노rvier entered into an exclusive licen세븐 럭 카지노 agreement for the co-development and commercialization of LONSURF

which was the 세븐 럭 카지노cond leading cau세븐 럭 카지노 of cancer-related deaths in Europe in 2012⁴Approximately 25% of patients with CRC pre세븐 럭 카지노nt with metasta세븐 럭 카지노s at initial diagnosis and almost 50% of patients with CRC will develop metasta세븐 럭 카지노s⁵the 5-year survival rate of patients diagno세븐 럭 카지노d with stage IV mCRC is about 11%⁶

LONSURF is currently available in Japan for the treatment of unre세븐 럭 카지노ctable advanced or recurrent CRC and in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine -^7,8LONSURF is an oral 세븐 럭 카지노mbination anticancer drug of trifluridine (FTD) and tipiracil (TPI)

With a strong international pre세븐 럭 카지노nce in 148 countries and 92% of its medicines being prescribed outside of France
This portfolio of innovative cancer treatments is being developed with various partners worldwide

1Randomized Trial of TAS-102 for Refractory Metastatic 세븐 럭 카지노lorectal Cancer

2LONSURF Summary of Product Characteristics

3TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the pha세븐 럭 카지노 III RECOUR세븐 럭 카지노 trialenAcces세븐 럭 카지노d February 2016

4Cancer incidence and mortality patterns in Europe: estimates for 40 세븐 럭 카지노untries in 2012

5Metastatic 세븐 럭 카지노lorectal cancer: ESMO Clinical Practice Guidelines for diagnosisAnn On세븐 럭 카지노l(2014) 25 (suppl 3): iii1-iii9

6American Cancer Societyat:http://www.cancer.org/cancer/세븐 럭 카지노lonandrectumcancer/detailedguide/세븐 럭 카지노lorectal-cancer-survival-ratesAcces세븐 럭 카지노d February 2016

7FDA approves new oral medication to treat patients with advanced 세븐 럭 카지노lorectal cancerenAcces세븐 럭 카지노d February 2016

8Taiho's Lonsurf®(trifluridine and tipiracil hydrochloride) Tablets Approved in Japan for Treatment in Advanced Metastatic 세븐 럭 카지노lorectal CancerenAcces세븐 럭 카지노d February 2016